NEW YORK, Dec. 18 — Dynacare, the clinical lab services company, will soon offer Visible Genetics' TRUGENE HIV-1 genotyping test in its central labs and local patient-service centers in the US and Canada, the groups announced late Monday.
The test uses a genotype report to identify variant strains of HIV, which allows for more accurate and effective drug therapy. Since the virus mutates rapidly and many strains are resistant to many of the first-order antiviral drugs, genotyping tests can streamline the drug-selection process.
The kit, approved by the US Food & Drug Administration in September, is the only HIV drug resistance test on the market, Dynacare said.
The company will offer the test in its 22 central labs, its 63 so-called rapid-response labs, and its 173 patient-service centers at a cost of $700, said Judi Ottmann, Dynacare's associate vice president for marketing. She added that several major insurance companies have already agreed to cover the test in their policies, and that Dynacare is actively involved in getting others to make the same pledge.
Visible Genetics, headquartered in Toronto, markets high performance DNA sequencing systems and gene analysis kits.